PubMed · 2002 · 29 citations · 5 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryPulmonary Drug DeliveryLiposomal FormulationsLiposome-based DeliveryLung TargetingNanocarriers For TherapeuticsPulmonary FormulationsPulmonary PermeationAnionic LiposomesDrug Delivery To The AirwaysLiposomal Delivery SystemsLiposomal NanocarriersLiposome Drug DeliveryLiposomesPulmonary Liposomes
The pulmonary route offers huge potential for delivering biotherapeutics not only to the lung itself but to other body organs as well. Before any liposomal formulation could be utilised for pulmonary drug delivery some critical points should be addressed, namely toxicity of the liposomal formulation, stability of the liposomes, drug entrapment efficiency and size variation of the formulation. Toxicity of some liposomes seems to be caused by the application of organic solvents or detergents during their manufacture, or employing cationic agents in their structure. Recent developments in the field have made it possible to prepare liposomes without using any organic solvent or detergent, examples of which are the polyol dilution method [1], and the heating method [2]. Anionic liposomes were prepared by the conventional thin-film hydration method and the heating method in which the lipids are brought to high temperatures (up to 120 o C) in the presence of glycerol (3 % v/v) [2-3]. In order to reduce the sizes of the vesicles the liposomal suspensions were extruded through polycarbonate filters of 100 or 400nm pore sizes. A gene transfer vector was constructed with the liposomes
5